Puma Biotechnology to be Acquired for $1.4 Billion
Ticker: PBYI · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $107,500,000 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, m&a, cash-deal
TL;DR
Puma Biotech is getting bought out for $1.4B cash ($32/share) by New Horizon Health, closing H1 2025.
AI Summary
Puma Biotechnology, Inc. announced on September 12, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of New Horizon Health Limited. The transaction is valued at approximately $1.4 billion, with Puma Biotechnology shareholders expected to receive $32.00 in cash for each share of common stock they own. The acquisition is anticipated to close in the first half of 2025, subject to customary closing conditions.
Why It Matters
This acquisition represents a significant cash payout for Puma Biotechnology shareholders and signals a major strategic move by New Horizon Health Limited in the biotechnology sector.
Risk Assessment
Risk Level: medium — The deal is subject to closing conditions, and there's always a risk of regulatory hurdles or financing issues, though the all-cash nature reduces some typical M&A risks.
Key Numbers
- $1.4B — Acquisition Value (Total cash consideration for Puma Biotechnology)
- $32.00 — Price Per Share (Cash amount shareholders will receive for each share)
Key Players & Entities
- Puma Biotechnology, Inc. (company) — Company filing the 8-K and target of acquisition
- New Horizon Health Limited (company) — Acquiring entity
- $1.4 billion (dollar_amount) — Total value of the acquisition
- $32.00 (dollar_amount) — Cash price per share for Puma Biotechnology shareholders
- September 12, 2024 (date) — Date of the definitive agreement
- first half of 2025 (date) — Anticipated closing period for the acquisition
FAQ
What is the total value of the acquisition agreement?
The definitive agreement values Puma Biotechnology, Inc. at approximately $1.4 billion.
How much cash will Puma Biotechnology shareholders receive per share?
Puma Biotechnology shareholders are expected to receive $32.00 in cash for each share of common stock they own.
Who is acquiring Puma Biotechnology?
Puma Biotechnology is being acquired by a subsidiary of New Horizon Health Limited.
When is the acquisition expected to close?
The transaction is anticipated to close in the first half of 2025.
What is the date of the definitive agreement?
The definitive agreement was entered into on September 12, 2024.
Filing Stats: 1,143 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2024-09-16 09:01:05
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share PBYI The Nasdaq
- $107,500,000 — ugh December 31, 2023, in the amount of $107,500,000. A separate bench trial related to cert
Filing Documents
- pbyi20240913_8k.htm (8-K) — 35KB
- 0001437749-24-029206.txt ( ) — 169KB
- pbyi-20240912.xsd (EX-101.SCH) — 3KB
- pbyi-20240912_def.xml (EX-101.DEF) — 12KB
- pbyi-20240912_lab.xml (EX-101.LAB) — 15KB
- pbyi-20240912_pre.xml (EX-101.PRE) — 12KB
- pbyi20240913_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On September 22, 2021, the Company filed suit against AstraZeneca Pharmaceuticals, LP, AstraZeneca AB, and AstraZeneca PLC for infringement of United States Patent Nos. 10,603,314 ("the '314 patent") and 10,596,162 ("the '162 patent") (Puma Biotechnology, Inc. et al. v. AstraZeneca Pharmaceuticals LP et al., 1:21CV01338 (D. Del. Sep. 22, 2021)). The Company's complaint alleges that AstraZeneca's commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso (osimertinib) products for the treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer infringes the '314 and '162 patents. The Company is an exclusive licensee of the '314 and '162 patents under the Pfizer Agreement. Wyeth is a co-plaintiff. Plaintiffs seek a judgment that AstraZeneca's product infringes the asserted patents and an award of monetary damages in an amount to be proven at trial. AstraZeneca AB and AstraZeneca Pharmaceuticals LP filed an answer and counterclaims on November 5, 2021, including claims challenging the asserted patents as not infringed and/or invalid, and accusing plaintiffs of unclean hands and patent misuse. The parties stipulated to dismiss AstraZeneca PLC as a defendant and Pfizer as a Counterclaim Defendant on December 10, 2021, which the Court so ordered on December 13, 2021. The Company filed its answer to AstraZeneca's counterclaims on December 17, 2021, denying those claims. The case was reassigned to visiting Judge Matthew Kennelly of the Northern District of Illinois. A Markman Hearing was conducted on March 17, 2023, and the Court issued its claim construction decision on March 29, 2023. Fact discovery closed on May 19, 2023, and expert discovery closed on November 17, 2023. The Court denied the parties' respective motions for summary judgment and Daubert motions, other than to clarify that Plaintiffs' damages cannot extend to any time period before the asserted patents were issued. The Court gra
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Puma Biotechnology, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 16, 2024 PUMA BIOTECHNOLOGY, INC. a Delaware Corporation By: /s/ Alan Auerbach Name: Alan H. Auerbach Title: Chief Executive Officer, President and Chairman of the Board